Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects. - Capello M; Sette A; Plantinga T; Thalhauser CJ; Spires VM; Nürmberger KB; Blum JM; Higgs BW; Garrido Castro P; Yu C; Costa Sa C; Fellermeier-Kopf S; et al. (Journal for immunotherapy of cancer, 2025)